Asset
Ibramvibart
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06523153 | phase1 | active_not_recruiting | 2024-08-28 | 2025-05-01 | Invivyd, Inc. | A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants |
| NCT07655180 | phase3 | recruiting | 2026-06-08 | 2026-08-01 | Invivyd, Inc. | Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine |
FDA applications (0)
This company has no applications containing this asset.